Alzheimer's Imaging Consortium.

Area of Science:

• Neurology
• Biomarker Research
• Alzheimer's Disease Diagnostics

Background:

• Clinical-biological diagnosis of Alzheimer's disease (AD) is increasingly recognized.
• Biological profiles aid in disease monitoring and prognosis, but real-world data from memory clinics is limited.

Purpose of the Study:

• To evaluate the prognostic value of AD core biomarkers in a memory clinic cohort.
• To compare the effectiveness of quantitative versus binary biomarker assessments for predicting clinical progression.

Main Methods:

• 211 subjects with cognitive concerns and 31 controls underwent AD pathological evaluations (amyloid-PET/plasma p-tau217, Florzolotau tau-PET).
• Biomarkers assessed included binary amyloid/tau status and quantitative tau burden (MTL, NEO).
• Clinical progression was the primary outcome; prognostic values were compared using ROC analysis.

Main Results:

• Age and sex were significant risk factors for clinical progression.
• Incorporating AD biomarkers individually significantly improved prognostic value (AUC 0.73-0.80) compared to demographics alone (AUC 0.57).
• Quantitative tau burden in neocortical areas showed the best prognostic added value, outperforming binary assessments, especially in the amyloid-positive subcohort.

Conclusions:

• AD core biomarkers show promise for enhancing clinical prognosis in memory clinics.
• Quantitative tau burden assessment is preferable to binary status for predicting AD progression.
• These findings support the use of advanced biomarker profiling for improved patient management in the AD continuum.